DR3/TNFRSF25 Death Receptor Drug Discovery Landscape & Assay Solutions

  • By admin
  • 05 Aug 2026
  • Comments

Market Intelligence for TL1A Axis Therapeutics and High-Purity Reagents for Autoimmune Disease Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for TNFRSF25/DR3 pathway drug discovery. While DR3 (TNFRSF25) is the specific death receptor for TL1A-mediated inflammation, this toolkit also covers related targets for comprehensive pathway and selectivity studies. Select your modality below:

Component / Network Product Description Product Link
Antigen DR3/TNFRSF25 ECD-Fc Fusion Protein (Human, Cyno, Mouse orthologs). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. View DR3/TNFRSF25 Products
Gene Delivery DR3/TNFRSF25 Full-Length Lentivirus (CMV promoter, Puromycin selection). For stable cell line construction and NF-κB/Apoptosis reporter assays. View DR3/TNFRSF25 Products
Benchmark Ab (α-DR3) Anti-DR3 Recombinant Antibody (Research Grade). Positive control for binding and functional assays. View DR3/TNFRSF25 Products
Benchmark Ab (α-TL1A) Anti-TL1A (Tulisokibart Biosimilar Sequence). Recombinant human IgG1 positive control for TL1A blockade assays. Sequence Verified. View TNFSF15 Products
Validator DR3/TNFRSF25 siRNA Set (3 unique targets). For knockdown verification and specificity controls. View DR3/TNFRSF25 Products
Ligand TL1A (TNFSF15) Trimeric Protein. Cognate ligand for DR3. Required for competitive binding assays. High purity (>95%). View TNFSF15 Products
Related Target A TL1A (TNFSF15) – Functional ligand for DR3; essential for ligand-competition and blocking assays. View TL1A Products
Related Target B DR4 (TNFRSF10A) – Apoptosis receptor for selectivity screening; avoid off-target apoptosis. View DR4 Products
Related Target C DR5 (TNFRSF10B) – TRAIL receptor for off-target apoptosis assessment. View TNFRSF10B Products
Related Target D TNFRSF12 (Fn14) – Fibrosis regulator; cross-talk with DR3 in IBD with fibrotic complications. View TNFRSF12 Products

Critical Assay Challenges & TarMart Advantages

Critical Assay Challenge The TarMart Advantage (Technical Spec)
TL1A Trimer Binding & Blockade Efficiency Sequence-verified ECD-Fc fusion preserves CRD4 binding interface. Suitable for SPR and ELISA blockade assays.
Cross-species Translation (Cyno/Mouse) Human/Mouse/Cyno ortholog proteins available with >95% purity. Conserved glycosylation patterns via HEK293 expression.
Death Receptor Selectivity (vs DR4/DR5) Homolog panel proteins (DR4, DR5) available for cross-reactivity ELISA/Flow cytometry screening.
Apoptosis vs NF-κB Signaling Bias Full-length lentivirus enables stable cell line construction for pathway-specific reporter assays (Death Domain intact).
False Positives in Binding Assays Validated siRNA included for specificity controls (confirm DR3-dependent binding).

Live DR3/TNFRSF25 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The TL1A/DR3 (TNFRSF25) axis has emerged as a premier target for autoimmune inflammation following the clinical validation of anti-TL1A antibodies in Ulcerative Colitis (UC) and Crohn's Disease (CD). With Merck's $10.8B acquisition of Prometheus Biosciences (Tulisokibart/PRA023), the industry is racing to exploit this pathway. While current leaders target the ligand (TL1A), next-generation strategies are exploring direct DR3 receptor modulation and bispecific approaches targeting both inflammation and fibrosis (via TNFRSF12/Fn14 cross-talk).

Future differentiation lies in:

  1. Fibrosis-Inflammation Integration: Dual targeting of DR3 (inflammation) and TNFRSF12 (fibrosis) for IBD with fibrotic complications.
  2. Tissue-Specific Biases: Developing molecules that bias toward NF-κB survival signaling vs apoptotic signaling in specific T cell subsets.
  3. Subcutaneous Delivery: Engineering high-concentration, low-viscosity antibodies for patient-administered IBD therapy.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Anti-TL1A mAb Merck (Prometheus), Teva, BioNTech UC, CD, Atopic Dermatitis DR3 Receptor Binding (Need high-purity TNFRSF25 ECD for blocking assays)
Anti-DR3 mAb Preclinical/Academic Autoimmune Diseases Apoptosis vs Survival Bias Assay (Need full-length lentivirus stable lines)
Fusion Protein (TL1A-Fc) Preclinical Immunotherapy Trimerization Validation (Need native conformation proteins)
Bispecific (TL1A x TWEAK) Emerging (Pipeline) Fibrostenotic CD Dual Receptor Occupancy (Need TNFRSF25 + TNFRSF12 protein panels)

Target Biology and Key Attributes

DR3 (TNFRSF25, UniProt Q93038) is a death receptor characterized by a functional Death Domain (evidence: UniProt domain). It mediates both pro-apoptotic and NF-κB survival signaling upon binding to its trimeric ligand TL1A (TNFSF15). Key naturally occurring mutations identified in dbSNP include: rs35771371, rs11800462, and rs34529016. These variants may impact receptor function, ligand binding, or downstream signaling, making them relevant for mechanistic studies and personalized medicine approaches. Understanding the structural and functional attributes of DR3 is critical for designing specific modulators.